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Abstract: Although kallikrein-related peptidase 10 
(KLK10) is expressed in a variety of human tissues and 
body fluids, knowledge of its physiological functions is 
fragmentary. Similarly, the pathophysiology of KLK10 
in cancer is not well understood. In some cancer types, 
a role as tumor suppressor has been suggested, while in 
others elevated expression is associated with poor patient 
prognosis. Active human KLK10 exhibits a unique, three 
residue longer N-terminus with respect to other serine 
proteases and an extended 99-loop nearly as long as in 
tissue kallikrein KLK1. Crystal structures of recombinant 
ligand-free KLK10 and a Zn2+ bound form explain to some 
extent the mixed trypsin- and chymotrypsin-like substrate 
specificity. Zn2+-inhibition of KLK10 appears to be based 
on a unique mechanism, which involves direct binding 
and blocking of the catalytic triad. Since the disordered 
N-terminus and several loops adopt a zymogen-like con-
formation, the active protease conformation is very likely 
induced by interaction with the substrate, in particular 
at the S1 subsite and at the unusual Ser193 as part of the 
oxyanion hole. The KLK10 structures indicate that the 
N-terminus, the nearby 75-, 148-, and the 99-loops are con-
nected in an allosteric network, which is present in other 
trypsin-like serine proteases with several variations.
Keywords: activation domain; anomalous signal; kal-
likrein loop; structural disorder; zinc inhibition.
Introduction
In search for down-regulated genes during breast cancer 
progression, KLK10 cDNA was originally cloned from 
radiation-transformed breast epithelial cells and desig-
nated normal epithelial cell-specific 1 (NES1) (Liu et  al., 
1996). KLK10 colocalizes with closely related genes in the 
chromosomal region 19q13.3–q13.4, forming the family 
of tissue kallikrein and kallikrein-related peptidases, 
abbreviated KLKs (Yousef et al., 1999). Gene expression of 
KLK10 is strongly influenced by estrogens, androgens and 
progestins (Luo et al., 2000, 2001c, 2003a).
Since both KLK10 mRNA and peptidase expression 
were lacking in breast and prostate cancer cell lines, a role 
for KLK10 as tumor suppressor was suggested (Goyal et al., 
1998). Downregulation of KLK10 was observed in breast, 
cervical, prostate, and testicular cancer as well as in acute 
lymphocytic leukemia (Luo et al., 2001c; Zhang et al., 2006). 
In line with the potential tumor-suppressing properties, 
overexpression of KLK10 in prostate cancer cells repressed 
cell proliferation, while apoptosis increased and glucose 
metabolism decreased (Hu et al., 2015). However, in other 
tumor types, such as ovarian, pancreatic, colon, and gastric 
cancer, upregulation of KLK10 indicates a tumor-support-
ive role (Yousef et al., 2005). High KLK10 tumor tissue and 
serum levels are linked with an unfavorable prognosis of 
ovarian cancer patients (Luo et al., 2001b, 2003b). Upregula-
tion of KLK10 and KLK10 peptidase expression in colorectal 
and gastric cancer correlate with poor prognosis for patients 
(Alexopoulou et al., 2013; Jiao et al., 2013). Moreover, many 
single nucleotide polymorphisms of the KLK10 gene were 
discovered, as well as alternative transcripts, however, their 
specific role in physiology and pathology remains unclear 
(Bharaj et  al., 2002; Kurlender et  al., 2005; Yousef et  al., 
2005; Batra et al., 2010).
By using immunofluorometric assays, KLK10 was 
detected in various human organs and body fluids, such 
as salivary glands, skin, colon, breast milk, seminal 
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plasma, cerebrospinal fluid, amniotic fluid, and blood 
serum (Luo et  al., 2001a). Further immunohistochemi-
cal studies identified KLK10 in many tissues, usually at 
higher expression levels in adult tissue, in particular 
in the female reproductive system (Petraki et  al., 2002; 
Shaw and Diamandis, 2007). Enzymatically active KLK10 
was identified in ovarian cancer ascites fluid, in which 
it seems to form complexes with α1-antitrypsin and the 
inter-α-trypsin inhibitor (Oikonomopoulou et  al., 2010). 
However, the physiological functions of KLK10 are still 
unclear. Biochemical data on the mutual activation of 
the KLKs revealed that recombinant KLK10 does not effi-
ciently cleave propeptides of other KLKs, which disfavors 
a participation in the known KLK activation cascades 
(Yoon et al., 2007, 2009).
KLK10 is classified in the MEROPS database as serine 
protease S01.246 of subclan PA(S) (EC 3.4.21.35) as the 
other 14 members of the human KLK family (Rawlings 
et al., 2012). According to a standard sequence compari-
son with (chymo-)trypsin-like enzymes, KLK10 possesses 
a 33-residue signal peptide, a 13-residue propeptide, 
with a potentially glycosylated sequon, and a 230-
residue catalytic domain, in which it shares 49% identi-
cal residues with KLK12 and 46% with KLK8 (Lundwall 
and Brattsand, 2008; Guo et al., 2014). In contrast to all 
other KLKs, KLK10 exhibits some unique features on its 
primary sequence, being the only KLK with a charged 
N-terminal residue, namely a glutamate in position 16, 
according to chymotrypsin numbering (Figure 1). All other 
KLKs possess a hydrophobic residue, such as Ile or Val, 
Figure 1: Structure-based alignment of KLK10 with KLKs 1, 2, 6 and bovine chymotrypsin (bCTRA) as numbering reference.
The degree of conservation is indicated by darker background. The catalytic triad residues, and the ‘fourth’ triad residue Ser214 are shown 
with black background. Secondary structure is depicted as red strands and yellow helices. Loops are shown as light gray lines or, in the case 
of the relevant surface loops, with additional black lines and names according to the central residue numbering scheme. Insertions with 
respect to chymotrypsinogen as Gln95A are designated 95a with small letters. The propeptide of KLK6 is indicated with bold letters. Active 
KLK10 exhibits some uncommon features compared to the other trypsin-like serine proteases, such as Glu16 and the extended N-terminus 
starting with Leu13. Also the hydrophobic 75-loop segment with four Leu residues is unusual, as well as the 99-loop, which resembles the 
classical kallikrein loop of KLKs 1, 2 and 3 in length. Instead of a Ser, Thr or Ala, KLK10 possesses the unique Pro190, which may contribute 
to the mixed tryptic/hydrophobic substrate preference. Finally, Ser193 replaces the highly conserved Gly193 of the oxyanion hole and may 
considerably influence substrate binding and turnover.
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which inserts into the activation pocket, in order to form 
the stabilizing salt bridge to the highly conserved Asp194 
(Goettig et al., 2010). Usually, disruption of this salt bridge 
results in complete loss of activity (Debela et al., 2006a). 
The unusual N-terminal sequence and lacking protease 
activity in biological samples, such as ascites fluid from 
ovarian cancer patients, led to the assumption that it is 
not a functional serine protease as opposed to the other 
KLKs (Luo et al., 2006; Zhang et al., 2006).
Remarkably, the recombinant E. coli-expressed con-
struct of KLK10 with a three-residue-longer N-terminus 
starting at Leu13, was active against fluorogenic substrates 
and yielded a typical specificity profile with a PSSCL 
library (Debela et al., 2006b). Tryptic specificity could be 
expected for KLK10, due to the presence of Asp189 at the 
bottom of the S1 pocket. Intriguingly, the PSSCL measure-
ments demonstrated an unusual dual specificity for the 
basic P1 residues Lys or Arg, and aliphatic ones, such as 
Met (Debela et  al., 2006b). A similar dual specificity is 
well established for the kininogen cleavage and inhibitor 
binding by KLK1 (Müller-Esterl et  al., 1986; Chen et  al., 
2000). Also, the 99-loop comprises an eight-residue inser-
tion, which is nearly as long as the kallikrein loop of the 
classical KLKs 1, 2 and 3 with their 11-residue insertion. 
Most unusual and in contrast to all other human KLKs, 
only KLK10 contains a Ser in position 193, whereas most 
serine proteases contain the highly conserved Gly193. The 
backbone amides of Ser195 and Gly193 form the oxyanion 
pocket, required for stabilization of the tetrahedral inter-
mediate during catalysis (Goettig et al., 2010).
Here, we present the purification, enzymatic charac-
terization, Zn2+ inhibition, and two crystal structures of 
the long N-terminal form of KLK10, which reveals several 
unique structural features, such as metal binding in the 
active site and a novel intermediate state among active 
KLKs, regarding the N-terminus and loops that surround 
the active site.
Results and discussion
An extended N-terminus is required 
for activity of KLK10
The first trials to obtain active human KLK10 with the 
standard residue number 16, a glutamate at the N-terminus 
of the mature enzyme were not successful. This finding is 
not surprising, as all other KLKs possess a hydrophobic 
residue in this position, typically Ile (nine cases), Leu 
(3), Val (KLK8), Ala (KLK9). Thus, the first hydrophobic 
residue before Glu16 was chosen, namely Leu13, which 
resulted in an active KLK10 peptidase, exhibiting typical 
activity against fluorogenic and chromogenic substrates, 
which allowed for substrate specificity profiling from 
the P4 to P1 positions (Debela et al., 2006b). Taking into 
account this unusual behavior, it is suggested that Leu13 
is designated Leu16 and the following three amino acids 
Asp16A, Pro16B, and Glu16C.
KLK10 was active against Tos-Gly-Pro-Lys-AMC, 
however, it seemed to prefer P1-Arg, as corroborated by the 
following examples of chromogenic and fluorogenic sub-
strates with increasing catalytic efficiency kcat/KM: Z-Gly-
Gly-Arg-AMC (2 m−1·s−1), BOC-Phe-Ser-Arg-AMC (95 m−1·s−1), 
BOC-Val-Pro-Arg-AMC (701 m−1·s−1), and Z-Gly-Pro-Arg-AMC 
(2076 m−1·s−1) (Debela, 2007). Z and BOC are the carboxy-
benzyl and tert-butyloxycarbonyl protecting groups of the 
peptide N-terminus, which correspond to aromatic and 
aliphatic hydrophobic P4 side chains and may occupy 
the S4 subsite. By measuring the KLK10 activity against 
Z-Gly-Pro-Arg-AMC with increasing Zn2+ concentrations, 
no activity was observed beyond 100 μm. The inhibition 
constant was determined as IC50 = 1.6 ± 0.1 μm, which is 
below the one of KLKs 2–5, 7 and 8 (Goettig et al., 2010).
Overall structure
Despite the presence of the small inhibitor PABA in the 
crystallization screen, KLK10 crystallized with a ligand-
free active site. The corresponding structure will be 
designated KLK10 and the one that was obtained from 
crystal soaks with 10 mm ZnCl2 as KLK10-Zn. Both crystals 
belong to space group P21 and contain two KLK10 mole-
cules per asymmetric unit, with only insignificant devia-
tions between the two independent copies (Figure 2A, B). 
Already the molecular replacement searches indicated 
that the target structure of KLK10 differed to some extent 
from other structures of mature KLKs. The calculation of 
root mean square deviations using 195 aligned residues 
resulted for KLK4 (PDB code 2BDG) in a RMSD of 1.63 Å, 
whereas KLK2 (4NFE) reached 1.43 Å. The zymogen-like 
conformation of mature KLK3 (3QUM) exhibited an RMSD 
of 1.47 Å and the only true zymogen structure among the 
KLKs, namely pro-KLK6 (1GVL), also had a relatively low 
RMSD with 1.45 Å for 187 aligned residues (Figure 2C). A 
similarly low RMSD of 1.44 Å was obtained with bovine 
trypsinogen (2TGT), which eventually was the best basis 
for a molecular replacement search.
Consequently, the overall fold of KLK10 resembles the 
prototypic serine protease trypsin, even more its zymogen 
trypsinogen, with some ingredients from other KLKs 
(Figure 2B). Active KLK10 consists of 232 amino acid resi-
dues, starts with Leu13 (16) and terminates with Asn246. 
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Figure 2: Overall structure of KLK10.
(A) Both KLK10 (yellow) and KLK-Zn (not shown) exhibit a similar dimer in asymmetric unit, with the active sites facing each other. The 99-loops 
of molecules A and B, shown in red, intercalate to some extent. A stretch of 10 residues from His95 to Arg96 is little defined in the electron 
density, comprising the whole insertion from Gln95A to Pro95H. The catalytic triad residues Ser195, His57, and Asp102 are depicted as ball-and-
stick models and labeled with their sequence numbers. (B) Monomer of KLK10 in standard orientation, with the catalytic triad as ball-and-stick 
models. In addition to the 99-loop, the other flexible regions of KLK10 are highlighted. The N-terminus (blue) is largely disordered and does not 
form the activating salt bridge to Asp194. Both the 75-loop (green), which is one residue shorter than most other KLKs, and the 148-loop (aqua-
marine) lack well-defined electron density for at least six residues. (C) Stereo representation of superposed KLK10-Zn (deep purple), pro-KLK6 
(salmon), and active KLK2 (light gray). The disordered regions of KLK10 or of KLK2 have been omitted, e.g. parts of the 99-loop. Catalytic triad 
residues, the specificity determining Asp189 and Pro190, as well as Asp194, which potentially forms the stabilizing activating salt bridge to the 
N-terminus, are depicted as stick models and labeled with sequence numbers. Trp141 is also shown, whose backbone amide forms a hydrogen 
bond to Asp194, as observed for other trypsin-like zymogens. The most relevant loops are labeled regardless of their disorder.
This single polypeptide chain is, as in most other KLKs 
cross-connected by six disulfide bridges and exhibits the 
kallikrein-typical cis-Pro219 in the 220-loop (Bode et al., 
1983). Otherwise, the structure of KLK10 differs considera-
bly from all other active KLKs, due to extended disordered 
stretches, starting with the N-terminus and the three major 
surface loops surrounding the active site (Figure 2B).
The flexible N-terminus and the active site 
loops of KLK10
Whereas classical KLKs, such as KLK1 or KLK2 mainly 
exhibit disorder in the 11-residue 99/kallikrein loop, 
mature KLK10 displays several disordered regions, includ-
ing the N-terminus, as well as the 75-, 99-, and 148-loops 
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(Laxmikanthan et al., 2005; Skala et al., 2014). Similar to 
the pro-form of KLK6, the first defined residue in the elec-
tron density is Ser20 in chain A and Pro21 in chain B, right 
before Cys22, which forms a stabilizing disulfide to Cys157 
(Gomis-Ruth et al., 2002). This finding confirms that in the 
present crystal structures the N-terminal residue Leu16 
(Leu13 in the common alignment) did not insert into the 
activation pocket (Figure 3A). In addition, the density 
around Asp194 does not indicate any salt bridge formation 
with the α-ammonium group, which would allow to favor 
the typical rigid conformation of active, mature trypsin-
like serine proteases (Bode et al., 1978; Huber and Bode, 
1978). Asp194 adopts a similar position as in pro-KLK6 or 
both bovine trypsinogen and chymotrypsinogen, with a 
Figure 3: The disordered N-terminus and surface loops of KLK10.
Similar to the same stretches in KLK10-Zn, both molecules A and B lack display disorder without significant electron density in these loops. 
Gray spheres indicate the likely trace of the disordered main chain segments. (A) The N-terminus of KLK10 is flexible and disordered as in 
zymogens, e.g. pro-KLK6. Electron density is missing from Leu13 (16) to Gly19, while Ser20 and Pro21 are better defined. (B) The 75-loop 
exhibits the unusual hydrophobic sequence of four Leu residues, with disorder from Asp71 to Leu77, comprising one deletion with respect 
to chymotrypsinogen. (C) The 99-loop exhibits the longest disordered stretch of KLK10 from His95 to Arg96, comparable to the same loop 
of KLK2, which is three residues longer. (D) The 148-loop lacks electron density from Ala146 to Tyr152 in both molecules A, whereas in mol-
ecules B the disorder extends to Gly155. Presumably, this loop adopts a wheel-like conformation, which distinguishes it strongly from active 
conformations and resembles much more the conformation in zymogens.
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hydrogen bond to the Trp141 backbone amide (Figure 2C). 
In contrast to pro-KLK6, whose activation pocket is largely 
occupied by the 191-loop from Lys188 to Gln192, only 
Gln192 is located in the corresponding relatively open 
pocket of KLK10 (Figure 3A). These facts alone could clas-
sify the present KLK10 variant as zymogen, albeit a rather 
active one. Zymogen activity is well known for another 
human serine protease, single-chain tissue type plasmi-
nogen activator (sc-tPA), which can adopt an active con-
formation by insertion of the Lys156 side chain into the 
activation pocket, with formation of a salt bridge between 
the Nζ atom and the carboxylate of Asp194 (Renatus et al., 
1997). Perhaps Lys150 or Lys153 of KLK10 might fulfill the 
role of such an activating side chain, but they seem not 
ideally positioned with respect to the activation pocket.
However, the unusual sequence Leu16-Asp16A-
Pro16B-Glu16C does not qualify as typical propeptide 
either, and may be capable of inserting into the activation 
pocket in solution, as a series of acetylation experiments 
of the N-terminus indicates. According to N-terminal 
sequencing KLK10 possesses a 100% free N-terminus, 
which upon acetylation is blocked to at least 75%. By con-
trast, in the presence of the chloromethyl ketone inhibitor 
PPACK acetylation of KLK10 results in only 25% blocked 
N-terminus. In addition, the activity against Z-Gly-Pro-Arg-
AMC drops to zero turnover for acetylated KLK10, which 
might represent the trapped zymogen state as present in 
the crystal structures.
The short 37 and 62-loops of KLK10 do not exhibit sig-
nificant alterations compared to KLK2 and pro-KLK6, in 
stark contrast to the larger loops that surround the active 
site cleft of KLK10. Nevertheless, the massive disorder in 
the major surface loops of KLK10 is neither typical for a 
zymogen nor easily explained. For example, bovine chy-
motrypsinogen (2CGA) is extremely well defined in the 
electron density, most likely because the N-terminal Cys1 
forms a disulfide to Cys122, which is not conserved in the 
KLKs and appears to suffice in rigidifying the otherwise 
flexible regions of the activation domain, including the 
longer loops around the active site and the S1 pocket. The 
75-loop of KLK10 with a single residue deletion compared 
to chymotrypsinogen comprises the unusual sequence 
DDHLLLLQGE, in which only Asp70 and Glu80 are con-
served residues. The electron density in all four copies of 
KLK10 is missing for Asp71 to Leu77, whereas pro-KLK6 is 
only disordered from residues 78–80 (Figure 3B). All KLKs, 
except KLK10, possess mainly charged or polar residues in 
this loop, which is in general rather well defined and can 
serve either for Zn2+ or Ca2+ binding, as in most trypsin-like 
pancreatic/coagulation proteases (Bode and Schwager, 
1975; Goettig et al., 2010). For KLK4 an activity regulating 
allosteric link between the N-terminus and the 75-loop has 
been observed similar to coagulation factor VIIa (Debela 
et al., 2006a).
Remarkably, the 99-loop of KLK10 exhibits an eight 
residue insertion, which is nearly as long as the 11 residue 
insertion of the three classical KLKs 1, 2 and 3. Seemingly, 
such long 99-loops can be relatively rigid upon glycosyla-
tion on the conserved Asn95 as in KLK1, while the binding 
of substrates or protein contacts may rigidify it as in 
KLK3, whereas it is largely disordered in glycan-free KLK2 
 (Laxmikanthan et  al., 2005; Menez et  al., 2008; Skala 
et al., 2014). Since the 99-loop of KLK10 is disordered from 
His95 to Arg96, including most of the kallikrein loop inser-
tion from Gln95A to Pro95H, its conformation remains 
hypothetical for this part (Figure 3C). Most of this stretch 
seems to block the active site, making a wide turn above 
the active site with the segment Arg97 to Asp99 facing the 
catalytic His57. Moreover, the 99-loop appears to contrib-
ute to the dimer formation of KLK10 in the crystal struc-
ture by mutually intercalating 99-loops near the active 
sites (Figure 2A).
Also, the 148-loop, which is usually well ordered in 
active trypsin-like proteases, exhibits extended disor-
der. This loop is known as autolysis loop of the coagu-
lation factors, whose cleavage can lead to inactivation 
as recently found for KLK2 (Guo et al., 2016). Both mol-
ecules A in the KLK10 and KLK10-Zn crystals lack elec-
tron density for Ala146 to Tyr151, whereas in molecules 
B the density is missing for Ala145 to Gly154 (Figure 3D). 
Again, the corresponding less defined stretch of pro-
KLK6 is shorter, ranging only from residues 148–151. 
However, the disordered segment of bovine trypsinogen 
extends even from residues 142–151 and beyond the fol-
lowing defined secondary structural elements, compris-
ing the 191- and 220-loops from residues 184–193 and 
217–223, respectively.
By contrast, the C-terminal segments of KLK10 are 
remarkably rigid and only minor disorder occurs in some 
side chains. Accordingly, the 176-, 191-, 205-, and 220-loops 
are well defined in the electron density in all four copies of 
KLK10, which is also independent of the Zn2+, bound in the 
catalytic center. Essentially, the 176-loop coincides with the 
conformations of active KLKs, such as KLK2 or KLK4. By con-
trast, the 191-loop, which shapes large parts of the S1-pocket 
adopts a zymogen conformation, e.g. with the Asp189 
turned towards the molecular surface (Figure 4). Then, the 
shortened 205-loop displays the expected conformation as 
in the active KLKs, and also the 220-loop is not too much 
altered when compared to active KLK2. Due to the disulfide 
Cys191–Cys220 the 220-loop conformation depends to some 
extent on the respective conformation of the 191-loop.
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Active site and substrate binding pockets
In order to judge the structural characteristics of KLK10 
with respect to its active peptidase conformation, the 
two KLK coordinate data sets with the smallest RMSD 
are further discussed. As mentioned before, active KLK2 
and pro-KLK6 bear the highest similarity to KLK10. Their 
surface loops share similar conformation or disorder to 
some extent. Intriguingly, the secondary structure scaf-
fold of all three molecules is essentially the same, even 
the catalytic triad residues are at their standard position 
(Figure  2C). However, the catalytic Oγ of Ser195 of mol-
ecule A in KLK10-Zn points directly to the Nε2 of His57, 
while in the other copies it is turned by about 90° towards 
the S1 pocket as in KLK2, or as in pro-KLK6 it is turned 
away by 180° with respect to the active protease confor-
mation. Moreover, the backbone amide of Ser193 in KLK10 
is relocated from an ideal position as part of the transi-
tion state stabilizing oxyanion hole, while its side chain 
points to the bottom of the S1 pocket without occluding it 
(Figure 4). Active serine proteases do not require a Gly193 
for stabilization of reaction intermediates, as shown by 
a mutational analysis of coagulation factor XIa elucidat-
ing that mainly β-branched residues in place of Gly193 
hamper substrate and inhibitor binding (Schmidt et  al., 
2004, 2008). This finding is corroborated by the example 
of Phe193 in the kallikrein-like, plasminogen activating 
snake venom TSV-PA, which does not bind extended poly-
peptidic substrates and inhibitors (Parry et al., 1998).
Despite the distortion of the KLK10 active site, 
which depends mainly on the zymogen-like conforma-
tions of the N-terminus and the 191-loop, the S1 pocket 
is relatively wide open and could accommodate a large 
side chain such as an Arg with little rearrangements 
(Figure 5). In the current conformation, the primary spec-
ificity determining Asp189 is not in the proper position to 
bind basic side chains. In case the S1 subsite adopts the 
standard conformation of a serine protease, the Asp189 
at its bottom should prefer P1-Arg and P1-Lys residues, in 
agreement with the profiling results, which show nearly 
equal acceptance of both basic residues (Debela et  al., 
2006b). The unusual KLK10 residues, Pro190 and Ala226, 
which line the distorted S1 pocket, substitute the common 
Ser190 and Gly226 of KLKs and explain very well that this 
S1 subsite additionally accepts aliphatic P1 residues, 
such as Met or probably Cys (Figure 4). The S2 pocket is 
relatively wide open: only the flexible Arg97 side chain 
seems to come close to potential P2 residues. Intrigu-
ingly, this residue could be the major determinant of the 
reported preference for Asp and, to a lesser extent, Glu in 
the S2 subsite (Debela et al., 2006b). The additional pref-
erence for Lys and Arg may depend on Asp99 at the back 
wall of this pocket. Tyr218 is the residue that defines most 
of the S3 subsite and may be responsible for the overall 
Figure 4: Stereo representation of the 191-loop in KLK10-Zn.
Side chains are represented as sticks and the most relevant residues are labeled, including the catalytic triad residues Ser195 and His57. 
It is worth noting that the loop is well defined in the 2Fo-Fc electron density (contour 1 σ), similar to the neighbouring 220-loop, to which it 
is linked by the disulfide Cys191–Cys220. Asp194 is in the typical zymogen-like position turned away from the activation pocket, as in pro-
KLK6 or trypsinogen. Nevertheless, the region of the potential salt-bridge formation with the N-terminus near Gln192 is not occluded as in 
typical zymogens. Ser193 is relocated from the oxyanion hole position, while Asp189 is turned from the bottom of the S1 pocket to the bulk 
solvent, in contrast to Pro190. This Pro residue might contribute to the mixed tryptic and hydrophobic P1-specificity of KLK10.
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unspecific character. The slight preference for acidic P3 
residues could depend on Arg96 and Arg97, if the little 
defined, disordered part of the 99-loop extends over the 
active site cleft. Finally, S4 was very unspecific in profil-
ing experiments and slightly disfavors basic residues, 
such as P4-His, Lys and especially Arg, while hydropho-
bic residues rank higher. The S4 subsite is shaped like in 
other mature KLKs, with a Trp215 as bottom and a Tyr172 
as the western wall viewed in standard orientation.
Zn2+ binding site at the catalytic center
Upon zinc soaking, one site per molecule of the KLK10-
dimer becomes visible in the electron density, which is 
most likely occupied by a Zn2+ ion (Figure 6A). An anoma-
lous Fourier map identified unambiguously an anoma-
lous scatterer at both sites, which confirms the presence 
of a transition metal. The metal cation is situated on the 
surface of both KLK10 molecules between the two cata-
lytic triad residues, His57 and Asp102, and is furthermore 
liganded by Asp99, together forming a trigonal first coor-
dination sphere (Figure 6B). In order to bind this Zn2+, the 
His57 side chain slightly moves away from Asp102, which 
also adjusts its side chain towards the metal ion to com-
plete the Zn2+ coordination with Asp99 (Figure 6C). The 
movement of the imidazolyl side chain of His57 is very 
subtle: it rotates modestly towards metal cation, not even 
disconnecting itself from Ser195 (Figure 6D). Average 
metal ion distances in both KLK10 molecules are 2.1 Å to 
His57 Nδ1, 1.9 Å to Asp99 Oδ2, and 2.0 Å to Asp102 Oδ2, 
which is in the range of comparable Zn2+ ligand distances 
in known structures (Figure 6C). According to the recent 
literature, the ideal distance of Zn2+ to His is 2.03  Å, and 
to monodentate Asp 1.99 Å, while bidentate distances 
range around 2.2 Å (Harding, 2001; Harding et al., 2010).
The mechanism of inhibition can be explained by 
a direct disruption of the catalytic triad, similar to the 
observations for other KLKs. However, the IC50 of 1.6 μm 
is the lowest for all investigated Zn2+-inhibited KLKs, 
which suggests that direct inhibition of the catalytic 
center is more efficient than for the other examples, 
which require additional conformational changes such 
as rotation of His57 out of its catalytic triad position 
and connection to ligands in the 99-loop (Goettig et al., 
2012). For example, the Zn2+-bound structure of KLK10 
is different from the crystal structure of the Zn2+-inhib-
ited tonin, where the Zn2+ is liganded by the imidazoyl 
side chains of His99, His97, and of the active site His57, 
which has rotated out of its normal site between Ser195 
and Asp102, to complete the Zn2+ coordination (Fujinaga 
and James, 1987). Thus, tonin is more similar to KLK7 
and KLK5, which have His99 at the Asp position repre-
senting one of the major ligands for Zn2+ binding close to 
the active site (Debela et al., 2007a,b). However, KLK10 
represents the first human serine proteases that holds a 
metal ion in the core of the active site and involves the 
two catalytic triad residues, His57 and Asp102. Depend-
ing on the respective tissue, the KLK10 activity might be 
tightly regulated by Zn2+.
Figure 5: Surface representations of KLK10 with electrostatic potentials.
(A) The electrostatic potential is contoured from −10 kBT/e (red) to +10 kBT/e (blue). Disordered regions were included for the electrostatics 
calculation and contribute to an overall positive electrostatic potential (KLK10 pI = 8.7), which is strongest around the 75-loop. This region 
corresponds to the anion binding exosite I of thrombin. The specificity pockets S4 to S1 are largely formed as in other active proteases, with 
S3 partially occupied by the 99-loop and considerable distortions of S1. (B) Disordered regions were omitted for electrostatics calculation 
and from the molecular surface representation. The flexible N-terminus and the disordered stretches of the 75-, 99-, and 148-loops are 
depicted as beige tubes.
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Figure 6: Zn2+ binding to the catalytic center of KLK10-Zn.
(A) Both Zn2+ sites in the KLK10-Zn dimer, with the metal ions displayed as gray sphere. Zn2+ is bound directly in the active site and coordinated 
by His57, Asp99 and Asp102. The trace of the partially disordered 99-loops is shown in red. (B) Close-up view of the Zn2+ site as stereo represen-
tation. The 2Fo-Fc electron density map can be contoured upto 7.0 σ, while two strong anomalous peaks are present, which coincide with Zn2+ 
sites. An anomalous Fourier map is depicted as orange grid, contoured at 3.5 σ. (C) The trigonal Zn2+ coordination sphere. Average ligand dis-
tances of both Zn2+ ions are 2.1 Å for His57, 1.9 Å for Asp99 and 2.0 Å for Asp102. (D) Superposition of the KLK10 Zn2+ structure (deep purple) and 
Zn2+ free KLK10 (yellow). The catalytic triad undergoes only minor relocations upon Zn2+ binding. The hydrogen bond network of the Zn2+-free 
structure is depicted as yellow dots. It should be noted that Ser195 and His57 in both strucutures do not exhibit active triad conformations. The 
Asp102 conformation is stabilized by the highly conserved Ser214, which has been termed the fourth residue of a catalytic tetrad. Zn2+ blocks 
the triad by interrupting the charge relay system in the region of the hydrogen that is shared by the His57 Nδ1 and the Asp102 Oδ2.
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Conclusion
In light of all the observations for the KLK10 structures, 
including the long disordered stretches, and taking into 
account the relevant comparisons with related struc-
tures, it appears that the KLK10 conformation repre-
sents neither a typical zymogen nor an active protease. 
Overall, it resembles less the slow zymogen-like and Na+ 
activated thrombin form and more coagulation factor 
VIIa, which exhibits an solvent exposed N-terminus and 
requires tissue factor as activator (Ruf and Dickinson, 
1998;  Huntington, 2009). Thus, KLK10 could be consid-
ered as sort of a changeling peptidase that is disguised 
as a zymogen, but ready for immediate protease action, 
which might be only prevented by the direct binding 
of Zn2+ to the catalytic triad. Structural and functional 
evidence from KLK10 are overwhelmingly speaking for 
the induced-fit model of enzymatic action (Koshland, 
1958). However, from a more elevated point of view, this 
model is no contradiction to the conformational selec-
tion model (Ma and Nussinov, 2010). In fact, both models 
can be reconciled in a very elegant way. In case of the 
recombinant KLK10 of this study, the variant is simply 
in a zymogen-like conformation. Most likely, only highly 
selective substrates can bind to this conformational 
state and, indeed, induce an active site conformation. 
In fact, the zymogen-like state exhibits an additional 
selective element with the Ser193 at the oxyanion pocket. 
Thus, conformational selection and induced fit are not 
two sides of the coin, they only represent two extreme 
views of a single phenomenon (Vogt and Di Cera, 2013). 
However, KLK10 shows that both positions per se do not 
suffice. The high flexibility of proteins, whenever it is 
required, and their persistent rigidity, whenever needed, 
are intrinsic to KLK10, a unique human protease, with 
some disordered stretches of high importance for its 
functionality. In addition to its plasticity, KLK10 activity 
is regulated in a so far unprecedented manner, by direct 
metal ion binding and concomitant interruption of the 
catalytic triad, which appears to be completely inde-
pendent of the overall conformational state as zymo-
genic protease.
Regarding the biological and pathophysiological 
function, we can only present some hypotheses. Despite 
the wide distribution of KLK10 in many tissues, natural 
substrates of KLK10 have not yet been characterized, 
except for a slow cleavage of pro-KLK sequences, which 
was explained with the presence of the unusual Ser193 
(Shaw and Diamandis, 2007; Yoon et al., 2009). Recently, 
it was demonstrated that pro-KLK3/PSA has considerable 
zymogen activity, which could extend its functionality, 
before it is captured by physiological inhibitors (Sangster-
Guity et  al., 2016). Similarly, KLK10 could remain in a 
latent, zymogen-like state for long periods of time, without 
binding inhibitors, such as serpins or α2-macroglobulin.
KLK10 is upregulated in gastric and ovarian cancer, 
which is associated with a poor prognosis for the patients, 
however, in breast cancer, it is down-regulated and was 
proposed as potential tumor suppressor. Similar to other 
extracellular proteases, such as the metalloproteinases 
MMP8 and ADAMTS1, or kallikrein-related peptidases, 
e.g. KLK8, KLK10 might contribute to signaling processes 
that induce apoptosis or autophagy in cancer cells (Lopez-
Otin and Matrisian, 2007). Intriguingly, the eminent tumor 
suppressor protein p53 is intrinsically disordered, which 
enables it to bind many diverse interaction partners (Old-
field et  al., 2008). Thus, it is tempting to propose that 
KLK10 recognizes various cancer-related substrates, due 
to its flexible segments around the active site, in particular 
the region of the N-terminus, the 75-loop and the 148-loop 
(Figure 5B). As already mentioned, KLK10 overexpression 
in prostate cancer cells increases apoptosis and reduces 
the glucose metabolism (Hu et al., 2015). In addition, the 
high concentration of Zn2+ in healthy prostate decreases 
in prostate cancer, while Zn2+ is elevated in breast cancer 
tissue (Ho and Song, 2009; Riesop et  al., 2015). On the 
one hand, high Zn2+ levels, i.e. above 10 μm, may inhibit 
the KLK10 protease activity in breast cancer, on the other 
hand, low Zn2+ concentrations in prostate tumors may 
increase the KLK10 activity and its tumor-suppressing 
function.
Materials and methods
Purification and characterization of the active protease
Expression, refolding and chromatographic purification of KLK10 
have been described before in detail (Debela et al., 2006b;  Debela, 
2007). KLK10 was expressed in E. coli M15(pREP4) cells, using a 
pQE30 vector (Qiagen). Inclusion bodies of KLK10 were dissolved 
in 8 m urea and the unfolded protein harboring an N-terminal His6-
tag was purified via a nickel-nitrilotriacetic acid-Sepharose column. 
Afterwards, the protein was dialyzed against 4 m urea, 100 mm NaCl, 
50 mm Tris/HCl (pH 8.0), and 0.005% Tween-20 for 12  h at room 
temperature. Refolding took place in 350 mm NaCl, 50 mm Tris/HCl 
(pH 8.0), 20 mm sucrose, 2 mm CaCl2, 100 mm L-arginine, 5 mm glu-
tathione (reduced), 0.5 mm glutathione (oxidized), 0.005% Tween-20, 
0.05% PEG 3350 for 36 h at 4°C. KLK10 samples were further puri-
fied or stored in 100 mm NaCl, 50 mm Tris/HCl (pH 8.0) and 0.005% 
Tween-20, such as during cleavage of the artificial pro-peptide by 
enterokinase and p-aminobenzamidine-Sepharose affinity chroma-
tography, in which the bound protease was eluted by increasing 
PABA concentration.
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The identity of KLK10 samples was confirmed by N-terminal 
sequencing. Moreover, the enzymatic activity of KLK10 was initially 
measured with Z-LR-AMC and Z-FR-AMC, using 20 nm protease in 
150 mm NaCl, 50 mm Tris-HCl (pH 8.0), and 0.005% Tween 20 and 
1% DMSO at 25°C. The standard substrate concentration was 250 μm 
and was varied for determining Michaelis-Menten kinetics. For Zn2+ 
inhibition kinetic measurements with Z-GPR-AMC Tris/HCl buffer 
(pH 7.0) was employed. Acetylation of the N-terminus was performed 
with 70 μl samples of 10 nmol KLK10, 18% (v/v) acetic anhydride, 
54% (v/v) methanol, 50 mm NH4(HCO3)2 (pH 6.5) for 30 min incuba-
tion at room temperature. Afterwards the samples were analyzed by 
N-terminal sequencing or used in activity assays, respectively.
KLK10 crystallization and data collection
Using the sitting-drop vapor diffusion method, native KLK10 crys-
tals were grown at 18°C from 2 μl protein solution, 10 mg/ml KLK10, 
which was concentrated from a solution of 30 nm KLK10 with 20 μm 
PABA, and 2 μl of 100 mm (NH4)2SO4, 100 mm MES (pH 5.6), equili-
brated against 500 μl reservoir solution. These crystals belong to the 
monoclinic space group P21 and contain two molecules per asym-
metric unit. For preparation of KLK10-Zn crystals, these crystals 
were soaked for 2 min in mother liquor with 10 mm ZnCl2. Upon soak-
ing, the crystals remained in monoclinic space group P21 with two 
molecules per asymmetric, but changed their cell constants to some 
extent (Table 1). Data were collected at the beamline BW6 of the DESY 
synchrotron at a wavelength of 1.05 Å (Hamburg, Germany).
Model building and refinement
The collected diffraction images were integrated with MOSFLM 
and scaled with AIMLESS of the CCP4 software package (Leslie and 
 Powell, 2007; Winn et al., 2011; Evans and Murshudov, 2013). Molecu-
lar replacement search was performed using the KLK4 chain A (PDB 
code 2BDG) in PHASER and resulted in the following scores: RFZ = 9.0, 
TFZ = 7.2, and LLG = +172 and an R-factor of 55.1 (Mccoy et al., 2007). In 
the following steps, the sequence of KLK10 (O43240, KLK10_HUMAN) 
from the UniProtKB database was employed (Uniprot, 2015). Using 
a model comprising 222 residues of bovine trypsinogen (2TGT) 
improved these values overall to RFZ = 8.5, TFZ = 7.7, LLG = +320, and 
an R-factor of 53.1. The correctness of the solution was checked by 
inspection of proper packing in the asymmetric unit and the unit 
cell, respectively, and composite omit maps calculated with the CCP4 
software. Molecular replacement with the refined solution for the 
unbound KLK10 coordinates afforded an RFZ = 9.6, a final TFZ = 27.9, 
LLG = +3288 and an R-factor of 37.1 for the KLK10-Zn data.
Iterative model building was performed in MAIN and COOT, fol-
lowed by refinement in PHENIX (Adams et al., 2010; Emsley et al., 
Table 1: Data collection and refinement.
Data collection   KLK10   KLK10-Zn
Space group   P21   P21
Unit cell dimensions (Å)   a = 53.60 b = 66.84 c = 57.90   a = 52.91 b = 67.04 c = 57.77
  α = 90° β = 104.29° γ = 90°   α = 90° β = 104.37° γ = 90°
Wavelength   1.05000   1.05000
Resolution range (Å) (outer shell)   51.94–2.70 (2.83–2.70)   55.96–2.65 (2.78–2.65)
Number unique reflections   10 481 (1355)   11 339 (1507)
Average multiplicity   3.3 (2.4)   3.1 (3.1)
Rmerge (%)   5.4 (15.7)   8.9 (50.6)
Rpim (all I+ & I−)   4.3 (13.4)   6.7 (38.5)
Rano   –   5.2 (32.0)
Completeness (%)   95.0 (93.3)   98.7 (99.9)
I/σ   14.4 (4.9)   8.1 (1.8)
CC(1/2)   0.99 (0.95)   0.99 (0.72)
Refinement    
 Resolution in refinement (Å)   51.94–2.70 (2.80–2.70)   55.96–2.65 (2.74–2.65)
 Completeness (%)   94.4 (90.8)   98.5 (99.9)
 Reflections in refinement   10 400 (982)   11 317 (1126)
 Working set/test set   9812 (921)/588 (61)   10 724 (1074)/593 (52)
 Rwork (%)/Rfree (%)   22.3 (28.2)/28.5 (35.2)   22.0 (28.1)/27.8 (38.4)
 Rmsd bond lengths (Å)   0.011   0.011
 Rmsd bond angles (°)   1.128   1.433
 Protein atoms [B-factor, Å2]   3107 [31.4]   3119 [37.4]
 Ions   7 SO42− [61.1]   2 Zn2+ [45.4] 6 SO42− [53.3]
 Solvent molecules   135 [26.8]   124 [36.8]
Ramachandran plot    
 Most favored regions   374 (93.6%)   368 (91.7%)
 Additionally allowed regions   26 (6.4%)   33 (8.3%)
 Outliers   0   0
PDB codes   5LPF   5LPE
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2010; Turk, 2013). The polypeptide main chain was overall well 
defined for all secondary structure elements, while the N-terminus 
and several surface loops were largely undefined. Rcryst and Rfree of 
the KLK10 data reached 22.3% and 28.5% at 2.70 Å resolution and 
for KLK10-Zn 22.0% and 27.8%, at 2.65 Å resolution. For the latter 
data an anomalous Fourier map was calculated in PHENIX with full 
model phases and the anomalous differences Δano based on Friedel 
pairs. More than 90% of the residues of both KLK10 and of KLK10-
Zn lies in the favored Ramachandran plot regions and the rest in 
the allowed regions according to MOLPROBITY (Table 1) (Chen et al., 
2010). The coordinates and structure factors were deposited in the 
protein database under the accession codes 5LPE and 5LPF. RMSD 
values were calculated using the Gesamt option of the SUPERPOSE 
software (Krissinel, 2012). All Figures were created with PyMOL 
(Delano, 2002).
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